Doxorubicin vs CMF in the adjuvant treatment of high risk breast cancer

被引：0
|
作者：
Semiglazov, VF [1 ]
Bozhok, AA [1 ]
Ivanova, OA [1 ]
Iranov, VG [1 ]
Golubeva, OM [1 ]
机构：
[1] NN Petrov Oncol Res Inst, St Petersburg, Russia
来源：
EUROPEAN JOURNAL OF CANCER | 1998年 / 34卷
关键词：
D O I：
10.1016/S0959-8049(98)80154-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
167
引用
下载
收藏
页码：S41 / S41
页数：1
相关论文
共 50 条
  • [21] Node negative breast cancer: adjuvant chemotherapy with CMF
    Moraes, A
    Cunha, F
    Thereza, M
    Leistner, A
    Loureiro, K
    Cunha, G
    Cunha, L
    Najas, R
    17TH INTERNATIONAL CANCER CONGRESS, VOL 1 AND 2, 1998, : 807 - 810
  • [22] Adjuvant CMF in breast cancer: 30 years' experience
    Nature Clinical Practice Oncology, 2005, 2 (3): : 118 - 118
  • [23] Abemaciclib as adjuvant treatment for high-risk early breast cancer
    Andrades, Ana Ganfornina
    Caballero, Silvia Fenix
    Olid, Alba Salguero
    Emilio, Jesus Alegre Del-Rey
    FARMACIA HOSPITALARIA, 2024, 48 (02) : 75 - 78
  • [24] ADJUVANT TREATMENT FOR STAGE-II BREAST-CANCER - A UNICENTER RAMDOMIZED TRIAL COMPARING CMF WITH CMF + TAMOXIFEN
    MAURIAC, L
    DURAND, M
    CHAUVERGNE, J
    AVRIL, A
    MAGE, P
    MAREE, D
    DILHUYDY, MH
    LETREUT, A
    WAFFLART, J
    BREAST CANCER RESEARCH AND TREATMENT, 1986, 8 (01) : 82 - 82
  • [25] RESPONSE TO SECONDARY-TREATMENT AFTER SURGICAL ADJUVANT CMF FOR BREAST-CANCER
    ROSSI, A
    TANCINI, G
    MARCHINI, S
    BONADONNA, G
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 190 - 190
  • [26] SIGNIFICANCE OF RELAPSE FOLLOWING ADJUVANT THERAPY WITH CMF OR 5-FU IN HIGH-RISK BREAST-CANCER
    CHLEBOWSKI, RT
    WEINER, JM
    LUCE, J
    HESTORFF, R
    LANG, JE
    REYNOLDS, R
    GODFREY, T
    RYDEN, VMJ
    BATEMAN, JR
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 146 - 146
  • [27] High dose epirubicin and cyclophosphamide (EC) vs cyclophosphamide, methotrexate, fluorouracil (CMF) as adjuvant chemotherapy in high risk premenopausal breast cancer patients (PTS). A prospective randomized trial
    Galligioni, E
    Cetto, G
    Nascimben, O
    Buonadaona, A
    Crivellari, D
    Molino, A
    Veronesi, A
    Graiff, C
    Barni, S
    Puccetti, C
    Ferrazzi, E
    Recaldin, E
    Sava, C
    Saracchini, S
    Sacco, C
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S36 - S36
  • [28] ADJUVANT TRIAL FOR STAGE-II RECEPTOR-POSITIVE BREAST-CANCER - CMF VS CMF+ TAMOXIFEN IN A SINGLE CENTER
    MAURIAC, L
    DURAND, M
    CHAUVERGNE, J
    BONICHON, F
    AVRIL, A
    MAGE, P
    DILHUYDY, MH
    LETREUT, A
    WAFFLART, J
    MAREE, D
    LAGARDE, C
    BREAST CANCER RESEARCH AND TREATMENT, 1988, 11 (02) : 179 - 186
  • [29] LOW-DOSE CMF VS CAMF TREATMENT FOR METASTATIC BREAST-CANCER
    CREECH, R
    HOLROYDE, C
    CATALANO, R
    KOONS, L
    MILLER, D
    ENGSTROM, P
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1976, 17 (MAR): : 259 - 259
  • [30] Safety comparison of weekly docetaxel vs CMF as adjuvant chemotherapy for elderly breast cancer patients (The ELDA trial)
    De Matteis, A.
    Nuzzo, F.
    Piccirillo, M. C.
    Gori, S.
    Morabito, A.
    Di Rella, F.
    Gravina, A.
    Labonia, V.
    Landi, G.
    Pacilio, C.
    Rossi, E.
    D'Aiuto, G.
    Thomas, R.
    D'Aiuto, M.
    Rinaldo, M.
    Signoriello, G.
    Gallo, C.
    Perrone, F.
    ANNALS OF ONCOLOGY, 2007, 18 : 51 - 51
12345